Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Conditions
Glioblastoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Department of Radiation Oncology, University Hospital Augsburg, Augsburg, Germany
Contact: Study coordinator (Klaus-Henning Kahl, Dr.) · klaushenning.kahl@uk-augsburg.de · +49 821 400 168564Department of Radiation Oncology, University Hospital Köln, Cologne, Germany
Contact: Study coordinator (Emmanouil Fokas, Prof. Dr.) · emmanouil.fokas@uk-koeln.de · +49 221 478 84763Department of Radiation Oncology, University Hospital Frankfurt, Frankfurt, Germany
Contact: Study coordinator (Markus Diefenhardt, Dr.) · markus.diefenhardt@unimedizin-ffm.de · +49 69 63 010Department of Radiation Oncology, University Hospital Freiburg, Freiburg im Breisgau, Germany
Contact: Study coordinator (Maren Paulmann, Dr.) · maren.paulmann@uniklinik-freiburg.de · +49 761 270 9463Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany
Contact: Study coordinator (Clemens Seidel, PD Dr.) · clemens.seidel@medizin.uni-leipzig.de · +49 341 971 8400Department of Radiation Oncology, Medical Faculty Mannheim, Mannheim, Germany
Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany
Department of Neurology, University Hospital Regensburg, Regensburg, Germany
Contact: Study coordinator (Cecilia Vasquez Robinet) · cecilia.vasquez-robinet@ukr.de · +49 941 944 18743Department of Radiation Oncology, Tübingen, Germany
Contact: Study coordinator (Barbara Gehler, Dr.) · pride_tuebingen@med.uni-tuebingen.de · +49 7071 29 68463
Study leads
Maximilian Niyazi, Prof. Dr.
Principal Investigator
University Hospital Tuebingen, Department of Radiation Oncology